YAbS







Aurograb Terminated Naked monospecific

Antibody Information

Entry ID 1877
INN None
Status Terminated
Drug code(s) Aurograb
Brand name None
mAb sequence source mAb human
General Molecular Category Naked monospecific
Format, general category Fragment
Format details scFv
Isotype (Fc) None
Light chain isotype TBD
Linker None
Ave. DAR None
Conjugated/fused moiety None
Discovery method/technology None

Therapeutic information

Target(s) S. aureus ABC transporter GrfA
Indications of clinical studies Methicillin-resistant Staphylococcal infections
Primary therapeutic area Infectious diseases

Development stage information

Phase lengths*
*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).
Most advanced stage of development (global) Terminated at Phase 3
Status Inactive
Start of clinical phase (IND filing or first Phase 1) November 15, 2002
Start of Phase 2
Start of Phase 3 January 15, 2004
Date BLA/NDA submitted to FDA
Year of first approval (global) None
Date of first US approval
INN, US product name None
US or EU approved indications None

Company information

Company Novartis Pharmaceuticals
Licensee/Partner None
Comments about company or candidate Novartis acquired NeuTec
A review of Phase 2 data indicated a lack of efficacy as an add-on therapy to antibiotics; NCT00217841 is listed as a Phase 3 study
Full address of company Basel, Switzerland
Europe
Switzerland
https://www.novartis.com/contacts

Description/comment

Target in https://patents.google.com/patent/US20080171054A1/en

Additional information

Anticipated events None
Factor(s) contributing to discontinuation Lack of efficacy